MedTrace Logo

Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets

NCT00473187 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2007-05-14

No results posted yet for this study

Summary

X-linked hypophosphatemic rickets (XLH) is characterized by rickets, disproportionate short stature, impaired renal phosphate reabsorption and vitamin D metabolism. Despite oral phosphate and vitamin D treatment, most children with XLH demonstrate reduced adult height. The main objective of the study is to determine the beneficial effects of recombinant human growth hormone (rhGH) therapy on body proportions after 36 month in these patients. Secondary objective is to monitor side effects of the therapy.

Conditions

  • Hypophosphatemic Rickets
  • Growth Disorders
  • Somatropin Therapy

Interventions

DRUG

somatropin

Sponsors & Collaborators

  • University of Rostock

    lead OTHER

Principal Investigators

  • Dirk Schnabel, MD · University Childrens Hospital - Charite, Berlin

  • Hagen Staude · University Childrens Hospital, Rostock

  • Dieter Haffner, MD · University Childrens Hospital, Rostock

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Completion
2009-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00473187 on ClinicalTrials.gov